Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome.

The expression of c-erbB receptors was immunohistochemically examined in paraffin embedded specimens from non-small-cell lung carcinomas. A total of 209 patients were enrolled [squamous-cell carcinomas (n=59), adenocarcinomas (n=130), large-cell carcinomas (n=15) and giant-cell carcinomas (n=5)]. The HercepTest kit scoring guidelines were used for the interpretation of positivity. C-erbB-1 was overexpressed in older patients, in squamous-cell carcinomas and in poorly-differentiated tumours, whereas c-erbB-2 overexpression with adenocarcinomas and poorly-differentiated tumours. C-erbB-4 overexpression correlated with advanced disease stage. The c-erbB-1/4 pair was the most commonly overexpressed and significantly correlated with female gender, while the c-erbB-1/2 pair with older age. Response to chemotherapy was significantly reduced in patients with tumours overexpressing c-erbB-1 receptor as well as the c-erbB-1/2 and c-erbB-3/4 receptor pairs. Patients' overall survival was significantly correlated with the co-expression of c-erbB-1 and c-erbB-4 receptors. These findings clearly suggest that specific receptors overexpression or co-overexpression is correlated with patients' disease control rate and outcome. A better understanding of the overexpression of the heterodimerized partners of c-erbB family receptors may provide a useful predictive indicator of response to molecular targeted therapies with c-erbB inhibitors.

E-cadherin expression on fine-needle aspiration biopsies in primary lung adenocarcinomas is related to tumor differentiation and invasion.

UNLABELLED: E-cadherin, a cell surface molecule that mediates cell-cell adhesion in normal epithelium, has been shown in recent studies of tissue biopsy to be related to tumor differentiation and invasiveness. The aim of the study was to explore if preoperative E-cadherin expression on fine-needle aspiration biopsy (FNAB) specimens can predict cell differentiation and mediastinal lymph node spread and therefore tailor treatment in patients with primary lung adenocarcinoma. We studied prospectively the relationship between E-cadherin expression on FNABs and the pathological features of 50 cases of primary lung adenocarcinomas, which were diagnosed cytologically and confirmed histologically post-operatively. Expression of E-cadherin was found in 36 (72%) cases. Decreased expression of E-cadherin was correlated with poor grade adenocarcinomas (low grade 33% vs. 100% in high grade, p < 0.005) and lymph node metastasis (positive 43% vs. negative 93%, p < 0.005). No relationship was found between E-cadherin expression and tumor size. CONCLUSION: E-cadherin expression of FNAB specimens can be helpful in predicting tumor cell differentiation, invasiveness and defining a subpopulation of patients with primary lung adenocarcinoma with possible poor outcome, which should be taken into consideration in the proper management of the disease.

Meningioangiomatosis with predominantly cellular pattern.

A case of meningioangiomatosis (MA), in a 10-year-old-girl with refractory complex partial and secondary generalized seizures, starting at the age of 8 years, is presented. MRI evaluation revealed a lesion located at the left frontal lobe; the patient underwent surgical lesionectomy. Histology revealed the lesion to have the features of MA. The patient is symptom-free a year postoperation. We report the histological, immunohistochemical and imaging findings in view of previous pertinent reports.

Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells.

BACKGROUND: Prostate cancer is one of the most frequent malignancies in males. Nevertheless, to this moment, there is no specific routine diagnostic marker to be used in clinical practice. Recently, the identification of a membrane testosterone binding site involved in the remodeling of actin cytoskeleton structures and PSA secretion, on LNCaP human prostate cancer cells has been reported. We have investigated whether this membrane testosterone binding component could be of value for the identification of prostate cancer. METHODS: Using a non-internalizable testosterone-BSA-FITC analog, proven to bind on membrane sites only in LNCaP cells, we have investigated the expression of membrane testosterone binding sites in a series of prostate carcinomas (n = 14), morphologically normal epithelia, taken from areas of the surgical specimens far from the location of the carcinomas (n = 8) and benign prostate hyperplasia epithelia (n = 10). Isolated epithelial cells were studied by flow cytometry, and touching preparations, after 10-min incubation. In addition, routine histological slides were assayed by confocal laser microscopy. RESULTS: We show that membrane testosterone binding sites are preferentially expressed in prostate carcinoma cells, while BPH and non-malignant epithelial cells show a low or absent binding. CONCLUSIONS: Our results indicate that membrane testosterone receptors might be of use for the rapid routine identification of prostate cancer, representing a new diagnostic marker of the disease.